Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DISC-3405 · 3 trials · 3 indications
Proportion of participants with treatment-emergent adverse events
Proportion of participants with changes in vital signs
Proportion of participants with changes in physical examinations
Proportion of participants with changes in electrocardiograms (ECGs)
Proportion of participants with changes in clinical laboratory results
Proportion of participants with treatment-emergent adverse events (TEAEs), changes in vital signs, changes in physical examinations, changes in electrocardiograms (ECGs), and changes in clinical laboratory results
| Arm | Type | Description |
|---|---|---|
| Within-participant dose escalation | EXPERIMENTAL | This is an open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405. |
| Single Ascending Dose of DISC-3405 | EXPERIMENTAL | - |
| Single Ascending Dose of Placebo | PLACEBO_COMPARATOR | - |
| Multiple Ascending Dose of DISC-3405 | EXPERIMENTAL | - |
| Multiple Ascending Dose of Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DISC-3405 | DRUG | DISC-3405 is administered subcutaneously. |
| Placebo | DRUG | Placebo is administered as a single dose IV infusion or subcutaneous injection |
Inclusion Criteria: 1. Aged 18 years or older at the time of signing the informed consent form (ICF). 2. Meet revised 2022 World Health Organization (WHO) criteria for the diagnosis of PV. 3. Complete blood count values at Screening of HCT \<45% or HCT \<48% if followed by a phlebotomy within 2 wee...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |